Beijing's Sinovac (NSDQ: SVA) reported that it now has the ability to manufacture two billion doses annually of CoronaVac®, its inactivated COVID-19 vaccine. So far, the company has delivered 200 million doses of the vaccine to over 20 countries, including China. Sinovac believes that over 100 million doses of CoronaVac have been administered during the rollout. In 2020, Sino Biopharma (HK:1177) invested $515 million in a Sinovac subsidiary to double production of the inactivated vaccine.

With the investment, Sinovac added a third production line, which has now been built and fully approved. After the investment, SinoBiopharm owns 15% of Sinovac Life Sciences at a valuation of  $3.5 billion.

The vaccine was approved for China use in February. CoronaVac showed varied efficacy readings of between 50.65% and 91% in various trials from Brazil, Turkey and Indonesia.

Sinovac’s COVID-19 vaccine  has received emergency use approval (EUA) by over 30 countries. The facility and quality management system of CoronaVac has been inspected by China, Brazil, Indonesia, Chile, Singapore, and Saudi Arabia, as well as the World Health Organization. Sinovac said the large-scale production of hundreds of batches of COVID-19 vaccine proved that the vaccine production process is controllable and the quality reliable.

Sinovac's product portfolio includes vaccines for:

• enterovirus71 (EV71),
• hepatitis A and B,
• seasonal influenza,
• H5N1 pandemic influenza (avian flu),
• H1N1 influenza (swine flu),
• varicella vaccine and
• mumps.

 The company is developing a number of new products including: 

• a Sabin-strain inactivated polio vaccine,
• pneumococcal polysaccharides vaccine,
• quadrivalent influenza vaccine and
• the SARS-CoV-2 (commonly referred to as COVID-19) vaccine.

See our other articles on Sinovac.

Disclosure: none.